MLchartDataset catalogue

Zabadinostat

Term · Oncology and biomedicine · MLC-T-ONC-017645

A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.

Table 1. Record
IdentifierMLC-T-ONC-017645
FieldOncology and biomedicine
Synonymshistone deacetylase inhibitor CXD101; HDAC inhibitor CXD101
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-017645",
  "term": "Zabadinostat",
  "field": "Oncology and biomedicine",
  "definition": "A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.",
  "synonyms": [
    "histone deacetylase inhibitor CXD101",
    "HDAC inhibitor CXD101"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/zabadinostat/"
}

Record 17,586 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.